US Edition
Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants with Relapsing Multiple Sclerosis (RMS)
Summary by Rush University Medical Center
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants with Relapsing Multiple Sclerosis (RMS)
Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants with Relapsing Multiple Sclerosis (RMS) abernotas Mon, 06/30/2025 - 13:30 Clinical Trial A randomized, double-blind, double-dummy, parallel-group study, comparing the efficacy and safety of remibrutinib versus teriflunomide in participants with relapsing multiple sclerosis, followed by extended treatment with open-label remibrutinib Rush University Medical Center NCT05…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
